NEW YORK, NY - Nov 24, 2014 - AiCure, an artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction.

Fatal overdoses from prescription opiates have quadrupled in the last 15 years. Opioids now cause more deaths per year than heroin, cocaine and benzodiazepines combined. Overall, the economic cost of opioid abuse is estimated to exceed $55 billion annually. Although adherence to therapy is associated with improved recovery, patients not taking their medication, taking it incorrectly, or giving it or selling it to others - which happens frequently - impedes patients and health systems from fully benefiting from treatment.

To address this problem, AiCure has developed a novel platform that can work on any smartphone. Unlike FaceTime® or Skype® where there is someone at the other end, in this case artificial intelligence automatically detects in real-time whether the person is taking their medication as prescribed. Patients who take incorrect doses or do not use the software are automatically flagged for immediate follow-up.

The National Institute on Drug Abuse (NIDA) has provided $1 million in funding to assess whether patients using the AiCure platform are more adherent and whether adoption of the system can improve treatment duration and reduce the risk of relapse. The large trial is being carried out with the Cincinnati Addiction Research Center (CinARC) at the University of Cincinnati. A total of 130 participants will be enrolled over the course of 18 months. Preliminary results of the trial are expected to be published in August 2015.

Connect with AiCure:

• Follow us on Twitter: @AiCureMed
• Find us on LinkedIn: AiCure

About AiCure

AiCure (AiCure.com) is an NIH-funded artificial intelligence company that has developed advanced facial recognition and motion-sensing technology to confirm medication ingestion. The monitoring and intervention platform has been developed as a SaaS model to maximize flexibility and scalability. The company has received over $3.4 million in National Institutes of Health (NIH) funding.

NIDA study funded under Award Number HHSN271201300036C. The content is solely the responsibility of the authors and does not necessarily represent the official views NIDA.